Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Mon, 23.09.2024
STRABAG SE
NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, INTO OR WITHIN THE UNITED STATES OF AMERICA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION IS UNLAWFULSTRABAG SE: Shares from 2024 capital increase being rebooked to regular ISIN AT000000STR
Last day of trading for shares in the temporary ISIN (AT0000A3 [ … ]
Mon, 23.09.2024
STRABAG SE
NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, INTO OR WITHIN THE UNITED STATES OF AMERICA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION IS UNLAWFULSTRABAG SE: Shares from 2024 capital increase being rebooked to regular ISIN AT000000STR
Last day of trading for shares in the temporary ISIN (AT0000A3 [ … ]
Mon, 23.09.2024
Valneva SE
Company Name:
Valneva SE
ISIN:
FR0004056851
Reason for the research:
Capital Raise
Recommendation:
Buy
from:
23.09.2024
Target price:
€7.70
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Simon Scholes
First Berlin Equity Research has published a research update on Valneva SE (ISIN: FR0004056851). Analy [ … ]
Mon, 23.09.2024
Valneva SE
Company Name:
Valneva SE
ISIN:
FR0004056851
Reason for the research:
Capital Raise
Recommendation:
Buy
from:
23.09.2024
Target price:
€7.70
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Simon Scholes
First Berlin Equity Research has published a research update on Valneva SE (ISIN: FR0004056851). Analy [ … ]
Mon, 23.09.2024
Aurubis AG
Aurubis AG releases preliminary operating result for 2023/24 and full-year forecast for 2024/25
Hamburg, September 23, 2024 — According to preliminary figures, Aurubis AG will generate operating earnings before taxes (EBT) of about € 75 million in Q4 of fiscal year 2023/24 (previous year: € 92 million)* and therefore not fulfill market expectation [ … ]
Mon, 23.09.2024
Aurubis AG
Aurubis AG releases preliminary operating result for 2023/24 and full-year forecast for 2024/25
Hamburg, September 23, 2024 — According to preliminary figures, Aurubis AG will generate operating earnings before taxes (EBT) of about € 75 million in Q4 of fiscal year 2023/24 (previous year: € 92 million)* and therefore not fulfill market expectation [ … ]
Mon, 23.09.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
Ladenburg, Germany, 23 September 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from [ … ]
Mon, 23.09.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
Ladenburg, Germany, 23 September 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from [ … ]
Mon, 23.09.2024
Artcline GmbH
ARTCLINE appoints Dirk Hessel as Managing Director and Prepares the Market Entry for Innovative Septic Shock Treatment
ARTCLINE is strengthening its management team with an experienced pharmaceutical leader to set up a sales force and accelerate strategic growth
ARTICE® is a therapy utilizing allogenic immune cells to strengthen the immunocompet [ … ]
Mon, 23.09.2024
Artcline GmbH
ARTCLINE appoints Dirk Hessel as Managing Director and Prepares the Market Entry for Innovative Septic Shock Treatment
ARTCLINE is strengthening its management team with an experienced pharmaceutical leader to set up a sales force and accelerate strategic growth
ARTICE® is a therapy utilizing allogenic immune cells to strengthen the immunocompet [ … ]